Camelid VHH Antibodies: Unique Origin, Structure, and Functional Advantages

What Are Camelid VHH Antibodies?

VHH antibodies are single-domain antibody fragments derived from the unique heavy-chain-only antibodies (HCAbs) of camelids, including alpacas, llamas, and camels. Unlike conventional immunoglobulin G (IgG) molecules, which consist of two heavy and two light chains, HCAbs are composed only of heavy chains. The variable region of these HCAbs, known as VHH, retains full antigen-binding capacity despite the absence of light chains.

VHH antibodies are significantly smaller (~15 kDa) than full-sized antibodies (~150 kDa) and are highly soluble and stable, which enhances their utility in therapeutic and diagnostic applications. Initially, scFv fragments were considered the minimal functional unit for antigen binding. However, the discovery of functional VHH antibodies and shark-derived VNARs demonstrated that single V-like domains could independently achieve high affinity and specificity.

Adaptation of Camelid Heavy Chain Antibodies (HCAbs)

The emergence of camelid HCAbs is believed to confer evolutionary advantages, particularly by enabling binding to epitopes that are sterically inaccessible to conventional antibodies. Their unique paratope architecture, which is characterized by extended complementarity-determining region 3 (CDR3) loops, allows access to concave or recessed antigenic sites, including enzyme active sites and viral envelope cavities. 

Structural features contributing to this binding versatility include non-canonical disulfide bonds that stabilize long CDR3 loops and support the overall integrity of the VHH domain in extreme pH or high-temperature environments. These adaptations are especially relevant for immune responses in camelids living under diverse physiological conditions. 

Most camelid HCAbs are derived from a small number of IGHV gene segments, primarily IGHV3-3 and IGHV3S53. These germlines are related to the human VH3 family but contain specific substitutions, particularly in framework region 2 (FR2), that increase hydrophilicity and prevent aggregation in the absence of light chains. Although these FR2 substitutions are common, they are not absolutely required for HCAb formation. Additionally, non-canonical cysteines in CDR1 and CDR3 often form disulfide bridges that stabilize the paratope and improve thermal resilience.

VHH Antibody Discovery →

Structural Features of the VHH Domain

Camelid VHH domains maintain a conserved immunoglobulin fold composed of nine β-strands. However, in the absence of a paired light chain, key structural adaptations arise:

• Hydrophobic to Hydrophilic Substitutions in FR2: In conventional VH domains, hydrophobic residues in FR2 mediate interactions with the VL domain. In VHHs, these are replaced with polar residues to prevent aggregation and promote solubility. 

• CDR Loop Compensation: The absence of VL-derived CDRs is compensated by elongated and structurally diverse CDR1 and CDR3 loops. These loops enhance antigen-binding surface area and introduce mutational diversity. 

• Disulfide Stabilization: Non-canonical disulfide bonds often form between CDR1 and CDR3, enhancing structural rigidity, especially under denaturing conditions. 

These structural elements collectively enable VHH antibodies to retain functional binding without the need for a heterodimeric partner. 

Solubility and Folding Efficiency of Camelid VHHs

Why VHHs Are Highly Soluble

The single-domain nature of camelid VHHs inherently reduces hydrophobic interfaces, promoting solubility in aqueous environments. This trait, combined with the hydrophilic substitutions in FR2, facilitates high-yield expression in microbial systems such as E. coli and Pichia pastoris. 

Folding Efficiency and Thermostability

VHH antibodies refold efficiently following denaturation, in part due to their compact and autonomous folding domains. Intradomain disulfide bridges contribute to their remarkable thermostability, allowing retention of function after exposure to high temperatures or harsh solvents. 

Impact on Formulation and Delivery

The robust biophysical properties of VHH antibodies make them suitable for non-parenteral delivery formats. They have been successfully formulated into: 

• Inhalable biologics for pulmonary delivery

• Oral formulations due to resistance to proteolytic degradation 

• Implantable or topical devices such as microchip sensors or slow-release hydrogels 

Their small size and ability to be genetically fused to other domains also make them ideal for bispecific constructs, antibody-drug conjugates (ADCs), or imaging probes. 

Advantages of Camelid-Derived VHH Antibodies

The advantages of VHH antibodies over conventional IgGs include: 

• Access to epitopes, including conserved and cryptic sites: VHH antibodies can bind to epitopes that are less accessible to larger antibodies.

• High thermal and chemical stability: VHH domains maintain activity at elevated temperatures, in acidic pH, or in denaturing agents. 

• Simplified genetic engineering: Their single-domain format simplifies cloning, mutagenesis, and expression for a wide range of constructs. 

• Improved tissue penetration: Their small size facilitates diffusion through dense tissues, enabling more effective target engagement in solid tumors or intracellular compartments. 

• Rapid clearance and reduced toxicity: Short systemic half-lives help mitigate off-target effects, which is especially advantageous in imaging and diagnostic applications. 

These features are further supported by empirical studies indicating that camelid VHHs can maintain antigen-binding activity after heating to 90°C or lyophilization. They also exhibit high refolding capacity, making them suitable for repeated freeze-thaw cycles or long-term storage in variable environments. 

VHH Antibody Discovery →

Applications of Camelid VHH Antibodies

Therapeutics

VHH antibodies are being investigated and used in the treatment of: 

• Cancer: As targeting modules for ADCs or CAR-T cell constructs 

• Infectious Diseases: As neutralizing agents against viruses and bacteria 

• Inflammatory Conditions: Due to their ability to penetrate tissues and modulate immune responses 

Clinical trials have demonstrated favorable pharmacokinetics and low immunogenicity in humans, especially when fused to Fc domains or albumin-binding motifs to extend half-life. 

Diagnostics

Their high stability and specificity make VHH antibodies ideal for use in: 

• Lateral flow assays 

• Electrochemical biosensors 

• ImmunoPET or SPECT imaging agents 

These tools benefit from VHH antibodies’ rapid clearance and tissue penetration, leading to high signal-to-noise ratios in imaging and point-of-care diagnostics. 

Research Tools

VHH antibodies are widely used as: 

• Affinity reagents for pull-downs, immunoprecipitation, or Western blotting 

• Intrabodies for functional interference within living cells 

• Tools for super-resolution microscopy, where their small size allows precise target labeling with minimal steric hindrance 

VHH Antibody Discovery →

How Biointron Supports VHH Discovery and Engineering

At Biointron, our camelid VHH discovery platform is designed to accelerate antibody development for therapeutic, diagnostic, and research purposes. 

• We immunize a dedicated alpaca from our 300+ herd for each project, ensuring a deep, target-specific immune response. 

• Our team constructs high-diversity VHH libraries (≥10⁸ clones) and runs tailored phage display campaigns to select VHHs with high affinity and broad epitope coverage. 

• Selected candidates undergo rapid expression, purification, and binding validation via ELISA, SPR, FACS, and functional assays (e.g., internalization or ADCC where applicable). 

• We routinely isolate VHHs with KD values ranging from 10⁻⁶ to 10⁻¹¹ M, depending on assay and target complexity. 

Deliverables include:

• Full sequence and affinity data 

• Prioritized hit and lead tables 

• Purified VHH samples 

• Next-step recommendations based on target class and intended application 

All VHH antibodies generated through our platform are fully owned by the client. 

References:

1. Asaadi, Y., Jouneghani, F. F., Janani, S., & Rahbarizadeh, F. (2021). A comprehensive comparison between camelid nanobodies and single chain variable fragments. Biomarker Research, 9. https://biomarkerres.biomedcentral.com/articles/10.1186/s40364-021-00332-6

2. Arbabi-Ghahroudi, M. (2022). Camelid Single-Domain Antibodies: Promises and Challenges as Lifesaving Treatments. International Journal of Molecular Sciences, 23(9). https://www.mdpi.com/1422-0067/23/9/5009

3. Bahrami Dizicheh, Z., Chen, I., & Koenig, P. (2023). VHH CDR-H3 conformation is determined by VH germline usage. Communications Biology, 6(1), 1-11. https://www.nature.com/articles/s42003-023-05241-y